- $3.36m
- -$14.29m
- 29
- 50
- 13
- 21
Annual balance sheet for Synaptogenix, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 5.8 | 34.2 | 37.5 | 28.7 | 17.7 |
| Net Total Receivables | 0.127 | — | — | — | — |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 6.73 | 35.5 | 38.6 | 30.5 | 17.7 |
| Net Property, Plant And Equipment | 0.022 | 0.02 | 0.022 | 0.019 | 0.013 |
| Long Term Investments | |||||
| Total Assets | 6.75 | 35.5 | 38.6 | 31.1 | 17.7 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 1.61 | 1.99 | 1.31 | 4.28 | 1.01 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 1.61 | 1.99 | 3.19 | 5.53 | 11 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 5.14 | 33.5 | 35.4 | 25.6 | 6.78 |
| Total Liabilities & Shareholders' Equity | 6.75 | 35.5 | 38.6 | 31.1 | 17.7 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |